IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: German study IV [82], one of the largest academic trials, included 1551 newly diagnosed CP-CML patients, and showed that the imatinib (800 mg → 600 mg) group was superior to the imatinib plus IFN group in MMR rates at 12 months (55% vs. 33%).